Sugi Predict

Sugi Predict / Compounds / SCHEMBL398722

SCHEMBL398722

SCHEMBL398722

Cc1ccc(NC(=O)Nc2cc(F)cc(CN3CCN(CC(=O)N(C)C)CC3)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.47
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PLK4 O00444 2/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPK10 P53779 3/20 0.39
▸ MAPK8 P45983 2/20 0.39
▸ WNT1 P04628 1/20 0.39
▸ CLK2 P49760 1/20 0.39
▸ CLK3 P49761 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ FAAH O00519 2/20 0.38
▸ OGA O60502 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ HTR1D P28221 1/20 0.38
▸ HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL402649 0.87 PLK4 (0.49) PLK4PAK4NTRK1TBK1MAPK10
SCHEMBL402839 0.86 WNT1 (0.48) MEN1KMT2AALDH1A1MAPK10MAPK8
SCHEMBL3209186 0.85 FAAH (0.44) PLK4PAK4NTRK1TBK1MAPK10
SCHEMBL398292 0.85 MAP4K4 (0.45) MAP4K4MEN1KMT2APLK4PAK4
SCHEMBL401393 0.85 CYP1A2 (0.48) MAP4K4MEN1KMT2APLK4PAK4
SCHEMBL436083 0.85 ACKR3 (0.49) OGAACKR3
SCHEMBL14465815 0.85 PLK4 (0.40) PLK4PAK4NTRK1TBK1MAPK10
SCHEMBL401660 0.84 NPC1 (0.49) PLK4PAK4NTRK1TBK1ALDH1A1
SCHEMBL399020 0.84 PIK3CA (0.50) MAP4K4PLK4PAK4NTRK1TBK1
SCHEMBL402023 0.84 KDM4E (0.43) PLK4PAK4NTRK1TBK1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-8101617-B2 Disubstituted ureas and uses thereof in treating heart failure AMGEN, INC. (US) 2012-01-24 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAP4K4 1580/4885MEN1 4319/4885KMT2A 4052/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MAP4K4 593/4885MEN1 4745/4885KMT2A 2999/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MAP4K4 1580/4885MEN1 4319/4885KMT2A 4052/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAP4K4 1698/4885MEN1 4344/4885KMT2A 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.